Pivotal Therapeutics Inc (PVTTF)

Overview

Pivotal Therapeutics Inc. is a specialty pharmaceutical company with a primary focus on the development and commercialization of products for the treatment of cardiovascular diseases and the promotion of overall health. The company is dedicated to addressing the clinical dietary management of cardiovascular disease in patients who are deficient in Omega-3 fatty acids, particularly eicosapentaenoic acid and docosahexaenoic acid. Headquartered in Woodbridge, Canada, Pivotal Therapeutics Inc. operates primarily in the United States and Canada, where its leading products, VASCAZEN and OMAZEN, are marketed for the management of Omega-3 deficiency in patients with coronary heart disease and for the maintenance of good health, respectively. The company is also engaged in the development of a wide range of products catering to different health needs, including the stabilization of vulnerable plaque in patients undergoing carotid endarterectomy.

Products and Services

• VASCAZEN

  This is Pivotal Therapeutics Inc.’s flagship product designed as a prescription-only medical food. VASCAZEN is formulated specifically for the clinical dietary management of cardiovascular disease in patients who have documented coronary heart disease and are deficient in Omega-3 fatty acids, eicosapentaenoic acid, and docosahexaenoic acid levels. It is available in the United States, addressing a critical need among patients for Omega-3 supplementation.

• OMAZEN

  OMAZEN is offered as a solution for the maintenance of good health by elevating Omega-3 fatty acid levels in individuals. This product is marketed in Canada and is available without a prescription, making it accessible for those looking to boost their Omega-3 intake for improved health and well-being.

• Benefishial Product Line

  The Benefishial product line is in development by Pivotal Therapeutics Inc. This range aims to address overall health, cardiovascular health, prenatal health, toddler's health, child's health, and pet's health through tailored formulations. Each product in this line is being designed to meet the specific nutritional needs of its target demographic, leveraging the health benefits of Omega-3 fatty acids.

• PVT-100

  Currently under development, PVT-100 is a drug aimed at the stabilization of vulnerable plaque in patients undergoing carotid endarterectomy. This innovation signifies the company’s venture into therapeutic solutions addressing the progression of cardiovascular diseases at a physiological level, potentially offering a novel approach to managing and preventing serious cardiovascular events.